ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

UCB and Biogen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

UCBBiogen
studies on the registry581549
open to participants now2428
phase 3 studies under way2019
reach primary completion within a year1415
programswith a study of their own in two years1611

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseUCBBiogen
Phase 1

UCB: 8 of its 16 programs at phase 1

  1. cizutamigphase 1
  2. Bimekizumab regimen 3 scphase 1
  3. Cizutamig will be dosed according to the protocol.phase 1
  4. CND261phase 1
  5. CND319phase 1

and 3 more — sign in to see them all

50%

Biogen: 3 of its 11 programs at phase 1

  1. BIIB142phase 1
  2. BIIB144phase 1
  3. BIIB145phase 1
27%
Phase 2

UCB: 3 of its 16 programs at phase 2

  1. galvokimigphase 2
  2. glovadalenphase 2
  3. donzakimigphase 2
19%

Biogen: 1 of its 11 programs at phase 2

  1. BIIB147phase 2
9%
Phase 3

UCB: 4 of its 16 programs at phase 3

  1. bimekizumabphase 3
  2. zilucoplanphase 3
  3. dapirolizumab pegolphase 3
  4. Fenfluraminephase 3
25%

Biogen: 5 of its 11 programs at phase 3

  1. felzartamabphase 3
  2. pegcetacoplanphase 3
  3. salanersenphase 3
  4. omaveloxolonephase 3
  5. diroximel fumaratephase 3
45%
Approved, new studies

UCB: 1 of its 16 programs at approved, new studies

  1. rozanolixizumabapproved, new study
6%

Biogen: 2 of its 11 programs at approved, new studies

  1. tofersenapproved, new study
  2. Dimethyl Fumarateapproved, new study
18%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
UCB6 readouts · 2 phase 3·

UCB, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. UCB5285phase 1 · Dec 13 · NCT07286682
  2. bimekizumabphase 3 · Dec 21 · NCT06921850
··

UCB, Mar ’27: 1 program whose next study reaches primary completion

  1. zilucoplanphase 3 · Mar 23 · NCT06961747
·

UCB, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. rozanolixizumabapproved, new study · May 6 · NCT05063162
  2. galvokimigphase 2 · May 17 · NCT07277660

UCB, Jun ’27: 1 program whose next study reaches primary completion

  1. CND261phase 1 · Jun 1 · NCT07052032
····
Biogen4 readouts · 2 phase 3·

Biogen, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. felzartamabphase 3 · Dec 1 · NCT06685757
·

Biogen, Feb ’27: 1 program whose next study reaches primary completion

  1. BIIB145phase 1 · Feb 2 · NCT07225517
··

Biogen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tofersenapproved, new study · May 26 · NCT07223723

Biogen, Jun ’27: 1 program whose next study reaches primary completion

  1. pegcetacoplanphase 3 · Jun 25 · NCT07215390
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

UCB

New programs 1

  • UCB0159phase 1 · first study · Sep 24 · Psoriasis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Biogen

New programs 1

  • BIIB147phase 2 · first study · Sep 28 · Amyotrophic Lateral Sclerosis

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionUCBBiogen
Myasthenia Gravisboth · compare here

UCB in Myasthenia Gravis: 3 programs

  1. zilucoplanphase 3
  2. cizutamigphase 1
  3. rozanolixizumabapproved, new study

Their studies: UCB’s studies of Myasthenia Gravis in search

Biogen in Myasthenia Gravis: 1 program

  1. felzartamabphase 3

Their studies: Biogen’s studies of Myasthenia Gravis in search

Psoriasisboth · compare here

UCB in Psoriasis: 2 programs

  1. bimekizumabphase 3
  2. UCB0159phase 1

Their studies: UCB’s studies of Psoriasis in search

Biogen in Psoriasis: 1 program

  1. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Psoriasis in search

Arthritis, Rheumatoidboth · compare here

UCB in Arthritis, Rheumatoid: 1 program

  1. CND261phase 1

Their studies: UCB’s studies of Arthritis, Rheumatoid in search

Biogen in Arthritis, Rheumatoid: 1 program

  1. Dimethyl Fumarateapproved, new study

Their studies: Biogen’s studies of Arthritis, Rheumatoid in search

Hemoglobinuria, Paroxysmalboth · compare here

UCB in Hemoglobinuria, Paroxysmal: 1 program

  1. zilucoplanphase 3

Their studies: UCB’s studies of Hemoglobinuria, Paroxysmal in search

Biogen in Hemoglobinuria, Paroxysmal: 1 program

  1. pegcetacoplanphase 3

Their studies: Biogen’s studies of Hemoglobinuria, Paroxysmal in search

Multiple Myelomaboth · compare here

UCB in Multiple Myeloma: 1 program

  1. cizutamigphase 1

Their studies: UCB’s studies of Multiple Myeloma in search

Biogen in Multiple Myeloma: 1 program

  1. felzartamabphase 3

Their studies: Biogen’s studies of Multiple Myeloma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: UCB 7 of 16 · Biogen 5 of 11 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.